Skip to main content
Premium Trial:

Request an Annual Quote

Fleury Group Bringing Ariosa's Harmony NIPD to Brazil

NEW YORK (GenomeWeb News) – Ariosa Diagnostics today said it has reached a deal with Fleury Medicina e Saude (Fleury Group) to provide Ariosa's non-invasive prenatal diagnostic test in Brazil.

The Fleury Group will distribute the Harmony Prenatal Test within its network of more than 3,000 clinical laboratories and hospitals throughout the country, which Ariosa said has an annual birth rate of almost 3 million.

The Harmony test is based on next-generation sequencing technology and provides a direct analysis of cell-free DNA in blood. According to Ariosa, the test has an accuracy rate above 99 percent for evaluating trisomy 21 risk, with a false positive rate of 0.1 percent. The test can be performed as early as 10 weeks of pregnancy.

Earlier this month, San Jose, Calif.-based Ariosa announced a deal with Advance Medical to bring Harmony to Mexico.

The deal is also the second such agreement in recent months to bring a sequencing-based NIPD test to Brazil. In August, Ariosa competitor Natera said the DASA Group would offer the San Carlos, Calif.-based company's Panorama test in that country.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.